ArticleFood science & nutrition2026
Octanoic Acid-Rich Enteral Nutrition Alleviates Sepsis-Associated Metabolic Disorders by Suppressing White Adipose Tissue Browning in Mice.
Article in Food science & nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sepsis is a life-threatening clinical syndrome accompanied by severe systemic metabolic disorders, and pathological white adipose tissue (WAT) browning is a core driver that exacerbates negative energy balance, skeletal muscle dysfunction and insulin resistance. Octanoic acid (OA), a C8 medium-chain fatty acid with superior ketogenic capacity, is a promising functional nutrient for sepsis intervention. This study aimed to investigate the protective effects and underlying mechanism of OA-rich enteral nutrition (EN) on sepsis-associated metabolic disorders. C57BL/6 mice were subjected to lipopolysaccharide (LPS) to establish sepsis models and received OA-rich EN with different concentrations; pharmacological activation of GPR81 and genetic activation of CTRP6 and p38 were used to verify the GPR81-CTRP6-p38 pathway. Results revealed that OA-rich EN dose-dependently increased serum β-hydroxybutyrate levels and decreased lactate accumulation in serum and WAT, with markedly better efficacy than conventional EN. OA-rich EN significantly inhibited LPS-induced upregulation of GPR81, CTRP6, phosphorylated p38 and UCP1 in WAT, mitigated WAT atrophy and abnormal browning, thereby alleviating excessive energy expenditure, body weight loss, skeletal muscle dysfunction and insulin resistance. Mechanistically, activation of GPR81, CTRP6 or p38 to promote WAT browning reversed the protective effects of OA-rich EN, confirming that OA-rich EN alleviated metabolic disorders by suppressing WAT browning via blocking the lactate-GPR81-CTRP6-p38 pathway. In conclusion, OA-rich EN enhanced hepatic ketogenesis to reduce lactate accumulation, thereby inhibiting the GPR81-CTRP6-p38 pathway and suppressing pathological WAT browning, ultimately alleviating sepsis-associated metabolic disorders. These findings provide a novel targeted nutritional strategy and theoretical basis for optimizing clinical nutritional support in septic patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.